Mainstay Medical (MSTY.I, MSTY ID)
Mainstay Medical is a specialist medtech company that is developing an innovative therapy (ReActiv8) with the potential to address the physiological origins of chronic, non-specific, low back pain. Management has applied for a CE mark for its ReActiv8 device following the successful completion of European clinical trials, paving the way for commercialisation in Europe in 2016. Prospective US approval, after a pivotal trial, could be achieved two to three years thereafter. With the addressable market for ReActiv8 estimated to be approaching 2m people across the US and EU markets, market size should not be a barrier to growth (while acknowledging competitive therapies). Commercial success can help Mainstay become a specialist medtech company with an increasingly attractive asset in a highly acquisitive sector.
|Fountain Healthcare Partners||10.7|
|Capricorn Health-tech Fund||6.1|